Patent Grant
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to announce that the University of Queensland has informed the Company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec® in India.
The granted patent in India is for a composition of matter patent for the particle itself as well as the manufacturing process relating to how the particle is made and matches the patents granted in the USA, Canada, Europe, Japan, Australia and China.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"The granting of this patent is a further indication of the strength of the intellectual property we have licensed from the University of Queensland and we now have all of the major global territories with granted patents for Nuvec®."
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Engage with us directly at N4 Pharma Investor Hub To hear more, visit | Via N4 Pharma Investor Hub Sign up at investors.n4pharma.com https://investors.n4pharma.com/link/0y5nKe |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44(0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44(0)20 3657 0050 |
| IFC Advisory Ltd Financial PR Graham Herring Zach Cohen | Tel: +44(0)20 3934 6630 |
About N4 Pharma
For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.